LACTOLOGY FOUNDATION

Overview

ATC class A02AD comprises antacid preparations that combine aluminum, calcium and/or magnesium salts, sometimes with additional agents such as simethicone or local anesthetics, to neutralize gastric acid and relieve dyspepsia, heartburn and acid-related upper gastrointestinal discomfort. These products are widely available over the counter and are typically used short term, on an as-needed basis, in otherwise healthy adults, including breastfeeding women.

Pharmacology and mechanism

• Aluminum hydroxide, magnesium hydroxide, magnesium carbonate and calcium carbonate act locally in the stomach lumen by neutralizing hydrogen ions and increasing intragastric pH, thereby reducing peptic activity and acid-related mucosal irritation.
• Simethicone, when present, acts as an antiflatulent by decreasing surface tension of gas bubbles, promoting their coalescence and expulsion without systemic absorption.
• Systemic absorption of aluminum and magnesium from standard-dose antacids is low in individuals with normal renal function, but absorbed fractions rely on renal excretion, which becomes clinically relevant in chronic use and in renal impairment.

Toxicology and safety profile

In patients with normal renal function and intermittent use, ATC A02AD combinations have a favorable systemic safety profile, with adverse effects predominantly gastrointestinal. Common dose-related reactions include constipation (more pronounced with aluminum and calcium), diarrhea (with magnesium salts), nausea, abdominal cramps and an unpleasant chalky taste.

Serious toxicity is rare but may occur with high doses, prolonged administration or in predisposed patients. Hypermagnesemia due to magnesium accumulation can lead to neuromuscular depression, hypotension and cardiac arrhythmias, particularly in severe renal impairment. Aluminum accumulation with chronic high exposure has been associated with osteomalacia and neurological impairment, again mainly in patients with compromised renal excretion.

Long-term high-dose aluminum-containing antacids may also cause hypophosphatemia by binding dietary phosphate in the gut, with potential clinical consequences for bone mineralization. Ingestions far exceeding therapeutic doses may produce significant electrolyte disturbances, metabolic alkalosis (especially with calcium carbonate) and, in extreme cases, require supportive care and correction of acid–base and electrolyte abnormalities.

Use during breastfeeding (lactation)

Available data and pharmacokinetic considerations suggest that antacid combinations of aluminum, calcium and magnesium produce minimal transfer into breast milk when used at standard doses. The active mineral components are poorly absorbed systemically, and where absorption occurs, maternal serum levels rise only modestly, which limits passage into human milk.

Clinical experience and expert reviews indicate that magnesium hydroxide and calcium carbonate antacids are generally considered compatible with breastfeeding, with no specific precautions listed for usual short-term use. Aluminum-containing antacids have not been associated with documented toxicity in breastfed infants when used intermittently by healthy mothers, although direct measurements of aluminum, calcium or magnesium concentrations in milk during antacid therapy are scarce.

Because only a very small fraction (typically less than 1% of the maternal dose for most medications) passes into breast milk, clinically significant exposure of the infant is unlikely at standard doses, especially when the product ingredients are poorly absorbed from the maternal gut. Nonetheless, precautionary principles favor using the lowest effective dose for the shortest possible duration and avoiding prolonged high-dose use in lactating women without clear indication.

Special populations and risk situations

In breastfeeding women with advanced renal impairment, the risk of systemic accumulation of aluminum and magnesium increases, theoretically raising the infant’s exposure via breast milk and the mother’s risk of toxicity. In such cases, alternative non–aluminum/non–magnesium therapies (for example H2 antagonists or proton pump inhibitors with established lactation safety) should be considered following specialist consultation.

Caution is advisable with chronic, high-frequency antacid intake in lactating mothers, especially when preparations are combined with other drugs, such as local anesthetics or multi-ingredient gastrointestinal syrups, because additional components may have less favorable lactation safety profiles. As with any maternal medication, infants should be observed for unexpected symptoms such as altered feeding, unusual sleepiness, gastrointestinal disturbances or rash, and medical evaluation sought if concerns arise.

Practical lactation recommendations

For healthy breastfeeding women requiring symptomatic relief of heartburn or dyspepsia, occasional on-demand use of A02AD antacid combinations at recommended doses is acceptable, provided renal function is normal and there is no underlying electrolyte disorder. Timing doses immediately after nursing or allowing a 2–4 hour interval before the next feed can further minimize peak drug levels in maternal blood and thereby in breast milk, although this is usually not essential for these low-absorption agents.

Long-term or frequent daily use should prompt clinical reassessment of the underlying gastrointestinal condition and a structured risk–benefit evaluation of continued antacid therapy versus alternative pharmacologic options with well-established breastfeeding safety. Product selection should favor simple formulations with clearly defined active ingredients and avoid unnecessary “extra strength” or sustained-release forms that prolong systemic exposure.